

## **Adverse Drug Reactions - Part I**



Course Author(s): Kristin A. Williams, DDS, MPH; M. Louay Taifour, BDS, DMD CE Credits: 3 hours Intended Audience: Dentists, Dental Hygienists, Dental Assistants, Dental Students, Dental Hygiene Students, Dental Assistant Students Date Course Online: 07/01/2017 Last Revision Date: 07/01/2019 Course Expiration Date: 06/30/2022 Cost: Free Method: Self-instructional AGD Subject Code(s): 10

Online Course: www.dentalcare.com/en-us/professional-education/ce-courses/ce536

**Disclaimer:** Participants must always be aware of the hazards of using limited knowledge in integrating new techniques or procedures into their practice. Only sound evidence-based dentistry should be used in patient therapy.

### **Conflict of Interest Disclosure Statement**

• The authors report no conflicts of interest associated with this course.

#### Introduction

This course presents the mechanisms of adverse drug reactions (ADRs), the 30 most common ADRs associated with the top 200 drugs dispensed by U.S. community pharmacies, and less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area. Emphasis is on those ADRs that have a pharmacokinetic or a pharmacodynamic basis and, with the exception of overdose, are the result of drug-drug, drug-food, drug-herbal, and drug-disease interactions with therapeutic doses of drugs.

Please note this is Part I of a two-part series. <u>Adverse Drug Reactions – Part II</u> discusses common immune-mediated and idiosyncratic ADRs related to the top 200 drugs dispensed by U.S. community pharmacies, less commonly noted ADRs affecting oral tissues, and drug-related carcinogenesis and teratogenesis.

## **Course Contents**

- Overview
- Learning Objectives
- Introduction
- "On-target" Mechanisms of ADRs
- "Off-target" Mechanisms of ADRs
- Cytotoxic Mechanisms of ADRs
- Clinical Frame of Reference Related to ADRs
  - Overdose Clinical Frame of Reference
  - Pharmacokinetic Drug-drug Interactions
  - Pharmacodynamic Drug-drug Interactions
  - Drug-food Interactions
  - Drug-herbal Interactions
  - Drug-disease Interactions
  - Cytotoxic Reactions
- Clinical Manifestations of ADRs
  - Overdose Clinical Manifestations
  - ADRs Affecting Oral Tissues
  - ADRs Affecting the Gastrointestinal System
  - ADRs Affecting the Liver and Biliary System
  - ADRs Affecting the Ears
  - ADRs Affecting the Cardiovascular System
  - ADRs Affecting the Respiratory System
  - ADRs Affecting the Urinary System
  - ADRs Affecting the Neuropsychiatric System
  - ADRs Affecting the Peripheral and Central Nervous Systems
  - ADRs Affecting the Endocrine/Metabolic System
- Summary
- Course Test
- References
- About the Authors

### **Overview**

This course presents the mechanisms of adverse drug reactions (ADRs), the 30 most common ADRs associated with the top 200 drugs dispensed by U.S. community pharmacies, and less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area. Emphasis is on those ADRs that have a pharmacokinetic or a pharmacodynamic basis and, with the exception of overdose, are the result of drug-drug, drugfood, drug-herbal, and drug-disease interactions with therapeutic doses of drugs.

## **Learning Objectives**

## Upon completion of this course, the dental professional should be able to:

 Discuss in general terms the approval process of new drugs and its limitations as they relate to ADRs.

- Discuss "on-target," "off-target," and cytotoxic mechanisms of ADRs.
- Develop a clinical frame of reference related to ADRs.
- Discuss the spectrum of potential ADRs affecting the head and neck area and various organ systems associated with dental therapeutics and the top 200 drugs dispensed by U.S. community pharmacies.

### Introduction

Clinicians and patients acknowledge the major role played by drugs in modern healthcare. Understanding how chemicals affect body homeostasis at the molecular level serves as the foundation for developing new therapeutic agents and provides the basis for rational pharmacotherapy. However, drugs seldom exert their beneficial effects without also causing **adverse drug reactions** (ADRs). This therapeutic dilemma lends credence to the statement that there are no "absolutely" safe biologically active agents.

With the exception of overdose, an ADR is defined by the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) as "a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function."<sup>1,2</sup> The phrase "response to a drug" means that a causal relationship between the therapeutic agent and the ADR is at least a reasonable possibility.

Based on data from the American Medical Association, the incidence rate of ADRs after the administration of FDA-approved drugs is approximately 1 in 123 (0.81%); or 2.2 million per year, 183,333 per month, 42,307 per week, 6,027 per day, 251 per hour, and 4 per minute.<sup>3</sup> Death rate extrapolation from the ADRs is 108,000 per year, 9,000 per month, 2,076 per week, 295 per day, and 12 per hour.<sup>3</sup> The term "incidence" refers to the annual diagnosis rate, i.e., the number of new cases of ADRs diagnosed each year.

The FDA has one of the most rigorous approval requirements in the world to authorize the marketing of new drugs (Table 1).<sup>45</sup> However, clinical trials cannot, nor are they expected to uncover every potential ADR. Pre-marketing study cohorts generally include less than 5000

subjects. ADRs that occur at a low frequency can easily be missed. In addition, pre-marketing clinical trials are of relatively short duration. ADRs that develop with chronic use and those that have a long latency period may also escape detection.

Most studies also exclude children, women, and the elderly and are seldom representative of the population exposed to the drug after FDA approval. Consequently, pre-marketing clinical trials detect only those ADRs that occur more frequently than 1 in 1000 subjects, which are then listed in the product's initial labeling (package insert) at the time of approval. In order to have a 95 percent chance of detecting an ADR with an incidence of 1 in 10,000 subjects, a population of 30,000 would have to be exposed to the drug.

ADRs can range from mild to severe illness and can lead to hospitalization, permanent disability, or death. The old term "side effect" as used in the

Preclinical testing (3 to 6 years)	Clinical trials (5 to 9 years)	Post-marketing surveillance (ongoing)
<ul> <li>Laboratory studies</li> <li>Isolation or synthesis of a new chemical</li> </ul>	<ul> <li>Phase I (several months):</li> <li>20 to 100 healthy volunteers</li> </ul>	<ul> <li>Monitoring for safety during post- marketing clinical use to determine the true risk-benefit profile of the new drug</li> </ul>
<ul> <li>Animal studies</li> <li>Assess safety and biological activity</li> <li>Pharmaceutical Company files an investigational New Drug (IND) application with the FDA</li> <li>FDA approval</li> <li>IND reviewed and approved by the institutional Review Board where the studies will be conducted</li> <li>Progress reports on clinical trials submitted to FDA annually</li> </ul>	Dosage range     Safety profile     Phase II (several months to several years):         • Several hundred volunteers with a specific disease         • Short-term effectiveness         • Adverse drug effects     Phase III (1 to 4 years):         • Several hundred to several thousand volunteers with a specific disease         • Long-term effectiveness         • Adverse drug effects         • Adverse drug effects         • Source and volunteers with a specific disease         • Long-term effectiveness         • Adverse drug effects         • Adverse drug effects         • Long-term effectiveness         • Adverse drug effects         • Adverse drug effects         • Adverse drug effects	<ul> <li>Pharmaceutical Company must continue to submit periodic reports to the FDA</li> <li>Case reports of adverse drug reactions</li> <li>Quality control records</li> <li>FDA may require additional clinical trials (Phase IV studies)</li> </ul>
	o FDA approval	
5000 to 10,000 biologically active agents evaluated	5 to 10 biologically active agents approved for clinical trials	1 biologically active agent approved for marketing

### Table 1. The Chronology of Testing and Introducing New Drugs.<sup>45</sup>

past, described not only negative (unfavorable) reactions; but, at times, concurrent positive (favorable) effects as well. The FDA recommends that this term no longer be used and should not be regarded as synonymous with ADRs.<sup>2</sup> Oral healthcare providers should be aware of the spectrum of ADRs and be actively involved in monitoring for and reporting such drug effects.

ARDs may be explained by one of five mechanisms: (1) "on-target" adverse reactions, (2) "off-target" adverse reactions, (3) cytotoxic reactions, (4) immune-mediated reactions, and (5) idiosyncratic reactions, i.e., reactions of unknown mechanisms.<sup>6</sup> A drug or drug class may produce toxic or adverse reactions by one or several of these mechanisms. In Adverse Drug Reactions – Part I, the discussion is limited to mechanisms (1), (2), and (3). Mechanisms (4) and (5) are discussed in Adverse Drug Reactions – Part II.

### "On-target" Mechanisms of ADRs

Drugs are intended to interact with specific receptors (intended receptors) in specific tissues (intended tissues). An "on-target" ADR may occur when a drug interacts with its intended receptor in the intended tissue.<sup>6</sup> With the exception of overdose, therapeutic doses of drugs may result in suboptimal or exaggerated responses because of drug-drug, drug-food, drug-herbal, and drugdisease interaction-related induction or inhibition of pharmacokinetic or pharmacodynamic processes.

Many drug targets are expressed in more than one cell type. An "on-target" ADR may also occur when a drug interacts with its intended receptor, but in an unintended tissue.<sup>6</sup> For example, intended targets for H<sub>1</sub>-histamine receptor antagonists are found in peripheral tissues, i.e., vascular smooth muscle, vascular endothelial cells, lungs, and nerve fibers. However, H<sub>1</sub>-histamine receptor antagonists with high lipid solubility cross the blood brainbarrier, interact with H<sub>1</sub>-receptors in the brain, and cause drowsiness.

A relevant example for oral healthcare providers relates to the use of local anesthetic agents (LAs) intended to block sodium channels in neuronal tissues at or near the site of its administration. However, an overdose; or rapid absorption, unintentional intravascular injection, low plasma protein binding, and slow metabolism or clearance of LAs can lead to high plasma levels. This can cause sodium channel blockade in the heart and cardiac depression-induced ventricular arrhythmia, atrioventricular block, and cardiac arrest.

## "Off-target" Mechanisms of ADRs

Very few drugs are completely selective; consequently, they can interact with different receptor types. An "off target" ADR can occur when a drug interacts with an unintended receptor either in an intended or in an unintended tissue.<sup>6</sup> For example, a  $\beta_2$ -adrenergic receptor agonist used to treat asthma may interact with  $\beta_1$ -adrenergic receptors in the heart and increase heart rate; and  $\beta_1$ -adrenergic receptor blocking agents targeting the heart may also antagonize  $\beta_2$ -adrenergic receptors in lungs and cause bronchoconstriction.

Two other examples of "off-target" ADRs, uncovered during post-marketing surveillance, resulted in the withdrawal of both drugs from the market. Terfenadine, an H<sub>1</sub>-histamine receptor blocking agent also interacted with unintended receptors (potassium channels) in an unintended tissue (heart) that caused fatal cardiac arrhythmias.<sup>6</sup> The anorectic agent, fenfluramine, targeting 5-HT serotonin receptors in the brain also interacted with 5-HT<sub>2B</sub> receptors in the heart causing myofibroblast proliferation and fatal valvular damage.<sup>6</sup>

## **Cytotoxic Mechanisms of ADRs**

Most drugs undergo metabolism into inactive metabolites in the liver and/or other tissues. Other drugs are pro-drugs, they must be metabolized into active metabolites to produce an effect; subsequently, these may undergo further metabolism into inactive metabolites. In some cases, however, the metabolites are unstable or reactive. For example, therapeutic doses of acetaminophen (APAP) are metabolized by conjugation into APAP-glucuronide and APAPsulfate; these compounds are nontoxic and are readily excreted.

A small percentage of APAP undergoes oxidation by CYP450 isoenzyme 2E1 into N-acetyl-p-benzoquinoneimine (NAPQI), a highly reactive metabolite. This toxic metabolite must undergo conjugation by glutathione. The APAP-glutathione conjugate is nontoxic and is readily cleared from the body. However, with supratherapeutic dosages glutathione stores are depleted. As NAPQI accumulates, it attacks cellular and mitochondrial proteins in the liver.<sup>6</sup> This, in a dose-dependent manner may lead to hepatic fibrosis or necrosis.

The main mechanisms responsible for fibrosis or necrosis include an oxidative pathway, which leads to the formation of reactive oxygen species (ROS) and a reductive pathway, which leads to the formation of reactive nitrogen intermediates (RNI).<sup>6</sup> Moderate doses of a toxic drug or metabolite activate mechanisms that result in programmed cell death (apoptosis) and tissue fibrosis. High doses of a toxic drug or metabolite activate mechanisms that lead to uncontrolled cell death and tissue necrosis.

# Clinical Frame of Reference Related to ADRs

Two or more drugs administered in therapeutic concentrations at the same time or in close sequence may act independently, may interact to increase or diminish the effect of one or more drugs, or may act to cause an unintended effect. All "on-target," "off-target," and cytotoxic ADRs have a pharmacokinetic or a pharmacodynamic basis and include those ADRs which, with the exception of overdose, are precipitated by drug-drug, drug-food, drugherbal, and drug-disease interactions with therapeutic doses of a drug.<sup>6</sup>

The risk of ADRs depends on the **margin of safety** between the dose of a drug required for efficacy and the dose that causes ADRs.<sup>6</sup> When the margin of safety is large, ADRs result primarily from overdose; when the margin of safety is small, ADRs may manifest at therapeutic doses. In addition to the dosage of the drug administered and drug-drug, drugfood, drug-herbal, and drug-disease interactions the margin of safety is also modulated by other patient-related variable such as genetic determinants and age.<sup>6</sup>

#### Overdose

Drug overdose occurs when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. Overdose may result when a young child or an adult with impaired mental abilities accidentally ingest a medication left within their reach. An adult, especially seniors or people taking multiple medications, can mistakenly ingest the incorrect medication or take the wrong dose of a medication. Some individuals may also be hyperreactive to a medication and even a therapeutic dose may be toxic.

#### Pharmacokinetic Drug-drug Interactions

Duration and intensity of drug action in both target and non-target tissues is predicated on the drug's plasma level and ability to reach intended or unintended receptors. In addition to dosage, the plasma level of a drug is modulated by the drug's rate of absorption, distribution, metabolism, and clearance.<sup>6</sup> These rates may be altered, i.e., induced or inhibited by concomitant drug therapy (Table 2). It is of note that some pharmacokinetic drug-drug interactions may at times be harnessed to optimize a drug's therapeutic effect.

Consider the pharmacokinetic ADR between opioid analgesics and APAP. The opioid by binging to  $\mu$ -receptors in the gastrointestinal tract increases the tone of the anterior portion of the stomach, decreases gastric motility, and delays the absorption of APAP, which takes place in the intestine. Another example, which affects metabolism, is the interaction between metronidazole and alcohol. Metronidazole inhibits the oxidation of an intermediary toxic metabolite of alcohol and causes severe nausea and vomiting.

#### Pharmacodynamic Drug-drug Interactions

To produce an effect in target and non-target tissues, a drug must be able to form a complex with its intended and/or unintended receptor. The intended or unintended effect produced by a given plasma level of a drug may result from chronic use or the presence of one or more drugs that lead to (1) changes in the number of available receptors or their ability to respond; or lead to (2) pharmacological, (3) physiological, and (4) chemical drug interactions, which at times may also be used to therapeutic advantage (Table 3).<sup>6</sup>

Consider the pharmacodynamic ADR between NSAIDs and antihypertensive agents. The inhibition of prostaglandin synthesis by

Туре	Examples of Mechanisms
	Drug A causes vasoconstriction at the site of administration and interferes with the systemic absorption of drug B administered at the same site
Absorption	Drug A delays gastric emptying and the systemic absorption of drug B absorbed primarily in the intestine
	Drug A neutralizes gastric acid (elevates gastric pH) and prevents the absorption of drug B
	Drug A forms chelates or complexes with drug B and prevents its absorption
	Drug A competes for plasma protein binding with drug B and increases its plasma level
Distribution	Drug A blocks the transport of drug B into hepatocytes and increases its plasma level
	Drug A blocks the transport of drug B into the intestinal lumen and increases its plasma level
Metabolism	Drug A induces a CYP450 isoenzyme responsible for the metabolism of drug B and decreases its plasma level
	Drug A, inhibits a CYP450 isoenzyme responsible for the metabolism of drug B and increases its the plasma level
	Drug A inhibits CYP450-Independent oxidation and causes accumulation of toxic intermediary metabolites of drug B
Renal clearance	Drug A competes for renal tubular transport with drug B and increases its elimination half-life
Biliary clearance	Drug A increases the synthesis of biliary proteins involved in the conjugation of drug B and decreases its plasma level

### Table 2. Pharmacokinetic Drug-drug Interactions.

NSAIDs increases vascular tone, which decreases the efficacy of antihypertensive drugs. Another example is a pharmacological drug-drug interaction between epinephrine and  $\beta_1$ -adrenergic receptor blocking agents. Since the  $\beta_1$ -adrenergic receptors are blocked, unopposed  $\alpha_1$ -adrenergic receptor activation

by epinephrine potentially can result in a hypertensive reaction.

Finally, note two examples of beneficial drugdrug interactions. Epinephrine activates  $\alpha_1$ -adrenergic-receptors causing vasoconstriction, delaying the systemic absorption of LAs, and

#### Table 3. Pharmacodynamic Drug-drug Interactions.

Туре	Mechanisms
Receptor	Drug A, when administered chronically, decreases the number of its own receptors or alters the adaptability of receptors to physiological events
alteration	Drug A, when administered chronically, increase the number of its own receptors or alters the adaptability of receptors to physiological events
Pharmacological	Drug A (an antagonist) and drug B (an agonist) compete for the same receptor site and as a function of their respective concentrations either prevent (antagonist) or produce (agonist) an effect
Physiological	Drug A and drug B interact with different receptors and enhance each other's action via different cellular mechanisms
	Drug A and drug B interact with different receptors and produce opposing effects via different cellular mechanisms
Chemical	Drug A interacts with drug B and prevents drug B from interacting with its intended receptor

increasing LAs' duration of action. Phentolamine mesylate, a competitive  $\alpha_1$ -adrenergic-receptor antagonist, when injected at the site of LA administration reverses the action of epinephrine as a function of its concentration causing vasodilation, increasing the rate of systemic absorption, and shortening the duration of soft tissues anesthesia.

#### **Drug-food Interactions**

Nutrients can act as mechanical barriers and protect the gastric mucosa from irritants; but they can also prevent drug-access to mucosal surfaces and reduce or slow the absorption of some drugs. Other mechanisms such as chemical interactions or chelating reactions with food components can produce inactive complexes. Conversely, a meal with high fat content may actually increase the absorption of some lipid-soluble drugs.

### **Drug-herbal Interactions**

Components of **grapefruit** inhibit CYP450 isoenzyme 3A4 and increase the plasma level of a number of drugs; for example, it can significantly enhance the anticoagulant effect of warfarin.<sup>6</sup> **Ginkgo biloba** inhibits platelet function; its use with acetylsalicylic acid (ASA), other nonsteroidal antiinflammatory agents (NSAIDs), and clopedigrel, which also interfere with platelet aggregation, increases the risk of bleeding.<sup>6</sup>

**St. John's wort** induces the CYP 450 isoenzyme 3A4 and decreases the efficacy of many drugs, including some prescribed by oral healthcare providers, e.g., benzodiazepines and macrolides antibacterial agents.<sup>7</sup> Large doses of **vitamin C** acidify the urine, inhibit the excretion of weak acids such as NSAIDs, acetaminophen, and tetracyclines (e.g., doxycycline and minocycline) and increase the plasma levels of these and other drugs.

## Drug-disease Interactions

**Cardiac diseases** can often result in reduced metabolic activity in general because of poor hepatic and renal perfusion.<sup>7</sup> **Hepatic dysfunction** can affect drug metabolism and biliary excretion.<sup>7</sup> **Renal insufficiency** can be expected to impair renal drug metabolism and clearance.<sup>7</sup> Uncontrolled **hypothyroidism** decreases the rate of drug metabolism and increases sensitivity to CNS depressants; and uncontrolled **hyperthyroidism** can increase the rate of drug metabolism and increases sensitivity to CNS stimulants.<sup>7</sup>

## **Cytotoxic Reactions**

Depending on the severity of the toxic insult cytotoxicity may manifest as apoptosis - programmed cell death; or necrosis - uncontrolled cell death.<sup>6</sup> Apoptosis is genetically directed self-destruction of DNA-damaged cells and, depending on the regenerating capacity of the tissue, may lead to fibrosis.<sup>6</sup> If the toxic insult is severe, programmed cell death cannot be accomplished and the cells undergo necrosis.<sup>6</sup> Necrosis is characterized by autolysis of damaged cells, inflammation, and damage to nearby healthy tissues.

## **Clinical Manifestations of ADRs**

The Council of International Organizations of Medical Sciences (CIOMS) in their publication "Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use" established guidelines for the diagnosis of ADRs and basic requirements for standardized reporting.<sup>8</sup> This is especially relevant since most reporting of ARDs is the result of spontaneous monitoring of single cases. The CIOMS codified ADRs under 21 major headings (Table 4) and defined 179 conditions considered reportable.

This discussion is based primarily on the 30 most common ADRs that can occur with therapeutic doses of drugs in the top 200 dispensed by U.S. community pharmacies.<sup>9</sup> The top 200 drugs are associated with 9829 individual potential ADRs. The 30 most common ADRs were determined by multiplying each potential ADR by the prescription volume of each drug in the top 200 (Box A). In addition, less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area are presented.

**DailyMed** is the official website for FDAapproved label (package insert) information.<sup>10</sup> The website provides a standard, comprehensive, up-to-date, look-up-anddownload resource for package inserts. The labeling information on the website is the most recent submitted to the FDA by pharmaceutical companies. The information is formatted to make it easy to read, includes strengthened warnings undergoing FDA review, and it is a reliable resource for information on potential ADRs related to specific drugs.

## Overdose

Generally, with overdose, the effects of drugs are exaggerated, ADRs become more pronounced, and other, unexpected reactions may be observed. Large overdoses of some medications may cause only minimal ADRs; yet, with other medications even smaller overdoses can cause severe toxicity, including death. A single dose of some medications can be lethal to a young child. Although clinical manifestations of drug overdose vary, signs and symptoms in Box B are suggestive of medication-induced toxicity in general.

The U.S. is in the midst of an **opioid overdose** epidemic. Opioid analgesics and heroin killed more than 33,000 people in 2015, more than during any other year on record. Nearly half of all opioid overdose deaths were related to prescription opioid analgesics.<sup>11</sup> An opioid overdose can reliably be identified by the presence of three clinical signs and symptoms referred to as the **"opioid overdose triad"**: (1) pinpoint pupils (miosis), (2) unconsciousness, and (3) respiratory depression (less than 12 breaths/min).<sup>12</sup>

Combining opioid analgesics with alcohol and other central nervous system (CNS) depressants increases the risk of respiratory depression and death. Indeed, opioids, alcohol, and sedatives are often present in fatal drug overdose. Risk factors for overdose with prescribed opioid analgesics include a history of substance abuse, high prescribed dosage, male gender, older age, mental health conditions, concurrent prescriptions of other CNS depressants (e.g., benzodiazepines), and lower socioeconomic status.

## **ADRs Affecting Oral Tissues**

The CIOMS does not provide a specific code for ADRs associated with oral tissues; however, it does include stomatitis and ulcerative stomatitis under the category of ADRs related to the gastrointestinal system.<sup>8</sup> In addition, xerostomia (ranked #28) and taste disturbances (ranked #30) are among the 30 most common ADRs identified with the

Table 4	Major	categories	of ADF	<b>₹s</b> . <sup>®</sup>
---------	-------	------------	--------	--------------------------

SOC 0100	Skin and appendages disorders	SOC 1020	Myocardial, endocardial, pericardial, and valve disorders
SOC 0200	Musculo-skeletal system disorders	SOC 1030	Heart rate and rhythm disorders
SOC 0300	Collagen disease	SOC 1040	Vascular (extra-cardiac) disorders
SOC 0410	Central and peripheral nervous system disorders	SOC 1100	Respiratory system disorders
SOC 0431	Vision disorders	SOC 1210	Red blood cell disorders
SOC 0432	Hearing and vestibular disorders	SOC 1220	White blood cell and RES disorders
SOC 0500	Psychiatric disorders	SOC 1230	Platelet, bleeding, and clotting disorders
SOC 0600	Gastrointestinal system disorders	SOC 1300	Urinary system disorders
SOC 0700	Kidney and biliary system disorders	SOC 1500	Fetal disorders
SOC 0800	Metabolic and nutritional disorders	SOC	Body as a whole – general disorders
SOC 1010	Cardiovascular disorders, general	1810	

top 200 drugs dispensed by U.S. community pharmacies.<sup>9</sup> Included under this heading are those orally-related ADRs that are of special interest to oral healthcare providers.

Many drugs can cause **xerostomia** (Box C).<sup>13-16</sup> Reduced salivary flow may be related to a drug's parasympatholytic or antimuscarinic effect in the CNS at parasympathetic and some sympathetic ganglia, or at parasympathetic and some sympathetic effector junctions. Other drugs cause fluid and electrolyte imbalance; glandular vasoconstriction; or alter fluid movement from plasma through acinar cells to the ductal system and, ultimately, into the oral cavity (Figures 1 and 2).

Many drugs, e.g., chlorhexidine, metronidazole, benzodiazepines, oral hypoglycemic agents, angiotensin converting enzyme (ACE) inhibitors, diuretics, amiodarone, calcium-channel blocking agents, and H<sub>1</sub>-histamine receptor antagonist have been implicated in **dygeusia** or **taste alterations** characterized as bitter or metalic.<sup>13-15</sup> The mechanisms of action of these drugs related to taste alterations are poorly understood, but appear to be associated with drug effects on trace metals (e.g., zinc) in plasma membranes.

01. Dizziness <sup>1</sup>	11. Thrombocytopenia <sup>1</sup>	21. Anxiety <sup>1</sup>
02. Nausea <sup>1</sup>	12. Abdominal pain <sup>1</sup>	22. Palpitation <sup>1</sup>
03. Headache <sup>1</sup>	13. Somnolence <sup>1</sup>	23. Tremor <sup>1</sup>
04.Vomiting <sup>1</sup>	14. Allergic reactions <sup>2</sup>	24. Arthralgia <sup>2</sup>
05. Diarrhea <sup>1</sup>	15. Dyspepsia <sup>1</sup>	25. Anorexia <sup>1</sup>
06. Rash <sup>2</sup>	16. Urticaria <sup>2</sup>	26. Nervousness <sup>1</sup>
07. Constipation <sup>1</sup>	17. Dyspnea <sup>1,2</sup>	27. Anaphylaxis <sup>2</sup>
08. Fatigue <sup>1</sup>	18. Hypotension <sup>1,2</sup>	28. Xerostomia <sup>1</sup>
09. Insomnia <sup>1</sup>	19. Depression <sup>1</sup>	29. Fever <sup>1</sup>
10. Pruritus <sup>2</sup>	20. Paresthesia <sup>1</sup>	30. Taste disturbances <sup>1</sup>
1. Possible primary	mechanisms of ARDs: "on-target," "off-tar	rget," cytotoxic reactions.

## Box A. The 30 Most Prevalent ADRs Associated With the Top 200 Drugs.<sup>9</sup>

#### Box B. General Signs and Symptoms of Drug Overdose.

- · Patient's skin may be hot and dry; or cool and sweaty
- Patient may complain of nausea, vomiting, abdominal pain, and diarrhea
- Patient may be sleepy, confused, or in a coma (cannot be aroused)
- · Breathing may be rapid or slow; deep or shallow
- Blood pressure and pulse rate may be increased or decreased; in some cases the pulse may be absent (e.g., not palpable); body temperature may be elevated
- Organs specific toxicity: for example, chest pain may suggest damage to the heart or lungs

Anticholinergics	Antineoplastic agents
Anticonvulsants	Antiparkinsonian drugs
Antidepressants	Anxiolytic agents
Antiemetics	Diuretics
Antihistamines	Muscle relaxants
Antihypertensive agents	Neuroleptic drugs
Antlinflammatory agents	Opioids

Box C. Major Drug Classes Causing Xerostomia.<sup>13-16</sup>



**Figure 1.** Antihistamine-induced Xerostomia.

### Stomatitis and ulcerative stomatitis

represent cytotoxic reactions to topically applied agents, e.g., LAs; or may result from the systemic administration of cytotoxic drugs, e.g., antineoplastic agents, which damage not only tumor cells, but all rapidly dividing normal cell populations.<sup>14,16</sup> The degree of tissue damage depends on the specific agent, dosage, dosage schedule, and patient-related variables. The lesions may appear as erythematous macules, patches, papules, plaques, or diffuse ulcerations (Figures 3 and 4).

Antibacterial and corticosteroid therapy is often complicated by superinfection with candidal organisms in oral tissues.<sup>14,16</sup> Antibacterial



**Figure 2.** Neuroleptic Druginduced Xerostomia.

agents kill bacteria allowing candidal species to successfully compete for nutrients. Corticosteroids promote gluconeogenesis and a hyperglycemic state facilitates the growth of the opportunistic candida species. **Candidiasis** may appear as white, raised, cottage cheeselike, or pseudomembraneous lesions that can be scraped off, leaving a red and sometimes hemorrhagic base.

**Gingival overgrowth** may be associated with the administration of calcium-channel blocking agents, phenytoin, and cyclosporine.<sup>13-16</sup> The mechanisms responsible are unclear, but they appear to be related to altered calcium metabolism and concomitant poor oral hygiene-



**Figure 3.** Topical ASA-induced Cytotoxic Reaction.



**Figure 4.** Lidocaine Ointment–induced Cytotoxic Reaction.



**Figure 5.** Hydrogen Peroxide-induced Cytotoxic Reaction.

related inflammation.<sup>13</sup> While the enlarged tissue is usually firm and painless, it may interfere with mastication; and, with significant inflammation, the patient may report pain and gingival bleeding (Figures 9 and 10).

ASA and other NSAIDs acetylate cyclooxygenase and inhibit platelet thromboxane A biosynthesis; clopidogrel inhibits adenosine diphosphate receptor-mediated platelet activity; and other medications such as antineoplastic agents may induce profound thrombocytopenia.<sup>13,15</sup> Clinical manifestations of platelet-related bleeding



**Figure 6.** Methotrexate-induced Cytotoxic Reaction.



**Figure 7.** Antibacterial Agent-induced Pseudomembraneous Candidiasis.



**Figure 8.** Inhaled (Topical) Corticosteroidinduced Hypertrophic Candidosis.

diatheses include **petechiae** (Figure 11), **purpura** (Figure 12), **ecchymosis** (Figure 13), **spontaneous gingival bleeding**, and increased potential for **perioperative bleeding**.

Oral anticoagulants (e.g., warfarin which inhibits vitamin K-dependent clotting factors, primarily Factor VII) and the parenteral anticoagulant heparin (which inhibits Factors II and X) reduce clot formation.<sup>13</sup> Clinical manifestations of anticoagulant-related bleeding diatheses include **hemorrhage**, which may be spontaneous or precipitated by trauma. Oral manifestations



**Figure 9.** Calcium-blocking Agent-induced Gingival Overgrowth.



**Figure 10.** Cyclosporine-induced Gingival Overgrowth.



Figure 11. ASA-related Petechiae.

may include spontaneous gingival bleeding (Figure 14), submucosal bleeding with **hematoma** formation, and increased peri- and post-operative bleeding.

Prevention and treatment of osteoporosis include the administration of antiresorptive agents such as bisphosphonates (BPs). A rare ADR related to BPs is **medication-related osteonecrosis of the jaw** precipitated by dentoalveolar trauma.<sup>17</sup> When BP molecules are released from the bone matrix some are internalized by osteoclasts resulting in inhibition of the mevalonate pathway essential



Figure 12. ASA/clopedigrel-related Purpura.



Figure 13. Warfarin-related Ecchymosis.



**Figure 14.** Heparin-related Spontaneous Bleeding.

for the synthesis of signaling proteins to activate osteoblast precursors. BPs also inhibit angiogenesis and are toxic to soft tissues.

### ADRs Affecting the Gastrointestinal System

Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, and anorexia are among the 30 most common potential ADRs associated with therapeutic dosages of the top 200 drugs dispensed by U.S. community pharmacies.<sup>9</sup> CIOMS does not list nausea and vomiting and considers abdominal pain an undesirable term to describe ADRs. When a patient complains of abdominal pain CIOMS recommends considering drug-induced colitis, pancreatitis, and peptic ulcer disease in the differential diagnosis.<sup>8</sup>

The physiologic purpose of **nausea** is to prevent food intake; that of **vomiting** is to expel food or other toxic substances present in the upper part of the gastrointestinal tract.<sup>18</sup> Nausea and vomiting occur in response to activation of the vomiting center either directly or through the chemoreceptor trigger zone (CRTZ). The CRTZ is outside the blood-brain barrier and is accessible to drugs circulating in the vascular compartment. NSAIDs, antibiotics, opioids, digitalis, and antineoplastic agents are examples of emetic drugs.<sup>18</sup>

**Diarrhea** and associated fecal urgency and incontinence may be defined as passage of loose, unformed stool with increased frequency.<sup>9,19</sup> Chronic diarrhea may be due to lactose intolerance, inflammatory bowel disease, malabsorption syndromes, endocrine disorders, irritable bowel syndrome, and the abuse of laxatives.<sup>19</sup> Common causes of acute diarrhea include viral and bacterial infections; and drugs such as antibacterial agents, Mg-containing antacids, antineoplastic agents, and colchicine.<sup>19</sup>

**Constipation** may be defined as the passage of excessively dry stool, infrequent stool, or stool of insufficient size.<sup>9,19</sup> It involves the subjective sensations of incomplete emptying of the rectum, bloating, flatus, lower abdominal discomfort, anorexia, malaise, headache, weakness, and giddiness. Common causes of acute constipation include antihistamines, opioid analgesics, neuroleptics, antidepressants, anticonvulsants, aluminum- and Ca-based antacids, Ca-channel blocking agents, and antiparkinsonian drugs.<sup>19</sup>

**Abdominal pain** is any pain in the topographical area of the abdomen. When describing an ADR, its relation to anatomical site and other symptoms should be specified.<sup>20</sup> For example, drug-induced **pancreatitis** is usually an acute condition characterized by upper abdominal pain accompanied by severe nausea and vomiting.<sup>9,21</sup> Some medications implicated in causing acute pancreatitis include corticosteroids, diuretics, oral hypoglycemic agents, estrogens, anticonvulsants, and antineoplastic agents.<sup>21</sup>

The principal symptom of **peptic ulcer disease** is also abdominal pain. Vomiting may also occur and the patient is predisposed to hemorrhage and perforation.<sup>9,22</sup> Hemorrhage may vary from slight bleeding to massive hemorrhage and the patient may vomit variable quantities of blood. If the blood goes down into the intestines, a large amount of altered blood makes the stools black and tarry (melena). The ulcerogenic effect of NSAIDs is well established and is attributable to inhibition of prostaglandin synthesis.<sup>22</sup>

Of particular concern to oral healthcare providers should be the patient complaining of lower abdominal pain, acute diarrhea with blood in the stool that is currently taking or has been prescribed in the recent past clindamycin or a broader spectrum penicillin or cephalosporin. The signs and symptoms are likely due to bacterial superinfection, e.g., an overgrowth of *C. difficile* in the gastrointestinal tract, a serious presentation of which is **pseudomembraneous colitis**.<sup>9</sup>

**Dyspepsia** is a sensation of discomfort or pain in the upper abdomen below the sternum. Patients may describe it as heartburn or indigestion and complain of feeling nauseous and bloated after eating, regurgitating (burping) food or liquid.<sup>18</sup> Drugs associated with acute dyspepsia include NSAIDs, opioids, antibacterial agents, oral hypoglycemic agents, ACEinhibitors, angiotensin II-receptor antagonist, corticosteroids, estrogens, anti-parkinsonian drugs, digoxin, niacin, fenofibrate, and SSRIs.<sup>18</sup>

**Anorexia** is defined as lack or loss of appetite for food.<sup>8,9</sup> It is to be differentiated from lack of appetite related to nausea, vomiting, or diarrhea; or hyporexia, decreased appetite; or anorexia nervosa, which is characterized by refusal to maintain normal body weight. With anorexia, limitation of food-intake and weight loss is not deliberate. Drugs that may have inhibitory effects on appetite and food intake include certain antibacterial agents, antineoplastic agents, fluoxetine, digoxin, quinidine, hydralazine, and vitamin A.

### ADRs Affecting the Liver and Biliary System

A potential complication of nearly every medication is hepatocellular liver injury.<sup>9</sup> One such drug discussed at length earlier is APAP.<sup>6</sup> During the past decade it has been identified as the leading cause of **acute liver failure** (ALF) in the United States and up to 50% of APAP-related cases of ALF are due to unintentional overdose.<sup>23</sup> Clinical signs and symptoms of APAP overdose include nausea, vomiting, abdominal pain, anorexia, and a few days later, elevated bilirubin presents as jaundice (Figures 15 and 16).<sup>24</sup>

In response to the problem of APAP-related overdosing, the FDA called upon healthcare professionals to discontinue prescribing combination drug products with more than 325 mg of APAP per formulation.<sup>23</sup> Ultimately, the FDA and the pharmaceutical industry have taken action to protect consumers from the risk of ALF by formally withdrawing from the market all prescription combination analgesics containing more than 325 mg of APAP per unit dose.<sup>23</sup> APAP, 650 mg per dose, q4h, may still be prescribed.

#### **ADRs Affecting the Ears**

**Dizziness** is the most common potential ADR associated with therapeutic dosages of the top 200 drugs dispensed by U.S. community pharmacies.<sup>9</sup> It is an imprecise term describing various related sensations such as faintness, a feeling of impending syncope; light-headedness; and a feeling of imbalance.<sup>25</sup> A false sensation of movement of self or the environment is called **vertigo**.<sup>8,25</sup> Because these symptoms overlap patients often use the terms dizziness and vertigo interchangeably.

Ototoxic drugs that affect the vestibular apparatus result in vertigo; cochlear ototoxicity results in **hearing loss**.<sup>8</sup> Ototoxic drugs may also cause **tinnitus** described by patients as noise in the ears such as buzzing, ringing, roaring, whistling, hissing, or pulsating.<sup>825</sup> Potentially ototoxic drugs include salicylates; antibiotics such as vancomycin, metronidazole, clindamycin, aminoglycosides (e.g., gentamycin and tobramycin), and macrolides; diuretics (e.g., furosemide); and antineoplastic agents (e.g., cisplatin).<sup>25</sup>

### ADRs Affecting the Cardiovascular System

**Hypotension** is the most common ADR related to the cardiovascular system.<sup>9</sup> It is defined



**Figures 15 & 16.** Hepatocellular toxicity in a patient with a history of alcohol abuse in association with therapeutic dosages of acetaminophen manifested as jaundice.

as blood pressure (BP) below normal for an individual. **Postural hypotension** is a decline from baseline of  $\geq$  20 mm Hg in the systolic BP and/or a decline of  $\geq$  10 mm Hg in the diastolic BP with symptoms of cerebral ischemia (syncope) following postural change.<sup>8,26</sup> Common drugs that produce postural hypotension include diuretics,  $\alpha_1$  and  $\beta_1$ -receptor blockers, nitrates, digitalis, ACE-inhibitors, and calcium channel blockers.<sup>26</sup>

**Syncope** is defined as sudden brief loss of consciousness due to cerebral ischemia.<sup>8,26</sup> In a young adult it is usually precipitated by a generalized, progressive autonomic discharge secondary to anxiety, pain, heat, or humidity. The initial adrenergic response to a stressor is followed by an overwhelming cholinergic surge just prior to unconsciousness. Syncope in patients over 50 years of age may likely be secondary to cardiovascular disorders (e.g., dysrhythmia, postural hypotension), hypoglycemia, or cerebrovascular insufficiency.<sup>26</sup>

**Palpitation** is a general term used by patients to describe an unpleasant awareness of forceful, rapid, or irregular heartbeat.<sup>8,26</sup> **Arrhythmia** is

defined as either a pulse rate < 60 beats/min or a pulse rate > 100 beats/min, the rhythm may be regular or irregular.<sup>8,27</sup> Arrhythmias are frequently associated with palpitation, syncope, dyspnea, angina pectoris, heart failure, or cardiogenic shock. Arrhythmia may result from drug-induced abnormal impulse generation or abnormal impulse conduction in the heart.<sup>27</sup>

Digoxin, a drug used to treat congestive heart failure, atrial flutter, and atrial fibrillation is also associated with causing cardiac arrhythmias. Macrolide antibiotics are known to cause cardiac arrhythmias characterized by prolongation of the QT interval, palpitations, hypotension, and chest pain. Macrolides-induced QT interval prolongation is amplified in combination with azole antifungal agents, some calcium channel blockers, and protease inhibitors because of CYP450 isoenzyme 3A4 inhibition.<sup>27</sup>

#### ADRs Affecting the Respiratory System

**Dyspnea** is ranked #17 among the 30 most common ADRs associated with the top 200 drugs dispensed by U.S. community pharmacies.<sup>9</sup> It is described as shortness of breath, breathlessness, inability to take a deep breath, suffocating, cannot get enough air, or pain on breathing.<sup>68,28</sup> Dyspnea is to be distinguished from impairment of expiratory airflow associated with chronic obstructive pulmonary disease.<sup>28</sup> Dyspnea may be caused by opioids,  $\beta_1$ -adrenergic receptor agonist, and intolerance to ASA, NSAIDs, and adenosine.

#### **ADRs Affecting the Urinary System**

The kidneys provide the final common pathway for the clearance of most drugs and their metabolites. Consequently, they are exposed to high concentrations of potentially toxic metabolites that can cause renal damage, especially in the presence of pre-existing renal disease.<sup>6</sup> For example, the chronic use of NSAIDs can lead to direct nephrotoxicity called **analgesic nephropathy**, related to the inhibition of prostaglandin synthetase resulting in reduced glomerular blood flow and **acute renal failure**.<sup>6829</sup>

**Urinary incontinence** is the involuntary loss of urine. Diuretics, alcohol, and caffeine increase urine production leading to increased frequency, urgency and nocturia.<sup>30</sup> Ca-channel blocking

agents, anticholinergic drugs, alpha-adrenergic agonists cause urinary retention and **overflow incontinence**.<sup>30</sup> Opioid analgesics can cause urinary retention, and like psychotropic drugs such as benzodiazepines, antidepressants, and antipsychotic agents may affect incontinence by blunting awareness to void.<sup>30</sup>

#### ADRs Affecting the Neuropsychiatric System

**Somnolence**, sleepiness or drowsiness, is a symptom characterized by a state of strong desire for sleeping or sleeping for unusually long periods.<sup>31</sup> The use of alcohol and street drugs, such as marijuana and heroin, can cause drowsiness.<sup>31</sup> Somnolence may also be caused over-the-counter medications such as antihistamines; and prescription drugs such as analgesics, and sleeping pills.<sup>31</sup> Drowsiness can also be caused by some herbal teas and supplements, such as valerian.<sup>31</sup>

**Insomnia** is a symptom characterized by difficulty in falling to sleep or to stay asleep. It is most often caused by psychiatric disorders, i. e., mood disorders and anxiety.<sup>31</sup> Drug-related insomnia may be associated with chronic use of drugs or result from drug withdrawal.<sup>31</sup> The use of alcohol, anticonvulsants, antidepressants, and thyroid hormones therapy may interfere with sleep. The withdrawal of CNS depressants such as opioids analgesics, benzodiazepines, alcohol, cocaine, and heroin may also lead to insomnia.

**Depression** is a mental state dominated by a lowering of mood and it often includes other symptoms such as anxiety, agitation, sleep disturbances, alteration in appetite, and feelings of unworthiness, and suicidal thoughts.<sup>8,32</sup> It is a frequent consequence of treatment with  $\beta_1$ -adrenergic receptor antagonists, digoxin, benzodiazepines, corticosteroids, levodopa, phenothiazines, and steroids.<sup>32</sup> It should be noted, however, that depression may be an appropriate response to transient life-stress situations.

**Anxiety** is the distressing experience of dread and foreboding; an unpleasant emotional experience characterized by nervousness, uneasiness, and fear.<sup>33</sup> Anxiety may be related to medical illnesses, psychiatric illness, or psychological illness. Dietary causes of anxiety include caffeine and monosodium glutamate (Chinese-restaurant

syndrome).<sup>33</sup> Symptoms of anxiety may be caused by antipsychotic drugs, anticholinergic agents, digitalis, amphetamines, cocaine; as well as withdrawal of alcohol or sedative-hypnotics.<sup>33</sup>

# ADRs Affecting the Peripheral and Central Nervous Systems

**Headaches** may be primary or secondary.<sup>34</sup> Primary headaches include migraine, cluster, and tension headaches. Secondary headaches may be related to extracranial causes (e.g., dental problems, sinusitis, and carotid artery disorders), intracranial causes (e.g., brain tumors and vascular disorders), and exposure to toxins and drugs. Secondary headache may be a symptom of exposure to monosodium glutamate (MSG); analgesic overdose; caffeine withdrawal; and treatment with estrogen and nitrates.<sup>34</sup>

**Fatigue** or **weakness** is a subjective feeling of tiredness and may have physical or mental causes.<sup>35</sup> Mental fatigue is due to prolonged periods of cognitive activity. Physical fatigue may be due to normal muscle exertion; or it may be caused by endocrine/metabolic problems, cardiopulmonary abnormalities, psychiatric disorders, vitamin deficiencies, or drug withdrawal.<sup>35</sup> Fatigue is common with medications such as antihistamines and  $\beta_1$ -adrenergic receptor antagonists.

**Tremor** is unintentional, rhythmic muscle activity involving to-and-fro movements (oscillations) affecting most commonly the hands, arms, head, face, and legs.<sup>36</sup> Tremor may be a symptom of a neurological disorder; it is most often associated with Parkinson's disease. It is also a well-recognized adverse reaction to such drugs as amphetamines, cocaine, thyroid hormones, mercury poisoning, corticosteroids, SSRIs, and alcohol abuse; and alcohol and benzodiazepines withdrawal.<sup>36</sup>

**Tardive dyskinesia** (TD) is an ADR related to long-term dopamine<sub>2</sub>-receptor blockade by antipsychotic drugs such as haloperidol, chlorpromazine, thioridazine, trifluoperazine, fluphenazine, and perphenazine.<sup>36</sup> Symptoms include oral dyskinesia, i.e., involuntary muscle movements characterized by continual chewing, intermittent darting of the tongue (fly fishing) and lip-smacking, pursing, or puckering.<sup>8</sup> TD is sometimes associated with abnormal, uncontrollable, writhing movements of the arms and/or legs.

**Paresthesia** is an unpleasant, abnormal sensation of tingling, numbness, or burning usually felt in the hands, feet, arms, or legs, but can also manifest in other part of the body.<sup>37</sup> Chronic paresthesia is many times a symptom of an underlying neurological disease or traumatic nerve damage. Drugs associated with paresthesia include LAs, long-term exposure to nitrous oxide, mercury poisoning, heavy metal poisoning, led poisoning, anticonvulsant drugs; and withdrawal of benzodiazepines and SSRIs.<sup>37</sup>

**Fever** is elevated body temperature, i.e., > 37.8° C orally.<sup>38</sup> It is regulated by the hypothalamic thermoregulatory center that maintains the internal temperature within a maximum fluctuation of 0.6° C. Fever results when something raises the hypothalamic set point and triggers peripheral vasoconstriction to preserve heat and shivering, which increases heat production.<sup>38</sup> Drugs that can increase heat production include amphetamines, cocaine, general anesthetics, and antipsychotic agents.<sup>38</sup>

# ADRs Affecting the Endocrine/Metabolic System

The treatment of diabetes mellitus includes daily administration of insulin and/or an oral hypoglycemic agent, which stimulate cellular glucose uptake. Increased rates of insulin absorption associated with increased skin temperature, heavy exercise, anxiety, infection, and pain lead to **hypoglycemia**.<sup>39</sup> Insulin and/ or oral hypoglycemic agents in the absence of adequate intake of carbohydrates also lead to hypoglycemia.<sup>39</sup> Signs and symptoms of hypoglycemia are epinephrine-, glucagon-, and neuroglycopenia-related.<sup>39</sup>

Adrenergic manifestations include twitching, tremor, anxiety, nervousness, sweating, pallor, cold and clammy skin, and mydriasis. Glucagon-related manifestations include hunger, boborygmus (rumbling, growling, or gurgling noise emanating from the patient's gut), nausea, vomiting, and abdominal pain. Neuroglycopenic manifestations include fatigue, weakness, lethargy, paresthesia, headache, subtle reduction in mental capacity, impairment of action and judgment, focal or generalized seizure, and coma.

### Summary

"On-target," "off-target," and cytotoxic ADRs, with the exception of overdose, are related to the use of therapeutic dosages of drugs and are predicated on the same pharmacokinetic and pharmacodynamic pathways as the therapeutic effects of drugs. Prerequisites to considering ADRs in the differential diagnosis of a patient's signs and symptoms include awareness that an ever increasing number of patients are taking more and more medications (polypharmacy) and familiarity with relevant literature about ADRs.

## **Course Test Preview**

To receive Continuing Education credit for this course, you must complete the online test. Please go to: <u>www.dentalcare.com/en-us/professional-education/ce-courses/ce536/start-test</u>

### 1. Which of the following statements related to adverse drug reactions (ADRs) is correct?

- a. Drugs seldom exert their beneficial effects without also causing ADRs this therapeutic dilemma lends credence to the statement that there are no "absolutely" safe biologically active agents.
- b. With the exception of overdose, an ADR is defined as "a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function."
- c. The FDA has one of the most rigorous approval requirements in the world to authorize the marketing of new drugs; however, clinical trials cannot, nor are they expected to uncover every potential ADR.
- d. All of the above.

### 2. All of the following statements related to ADRs are correct EXCEPT which one?

- a. In order to have a 95 percent chance of detecting an ADR with an incidence of 1 in 1,000 subjects, a population of 30,000 would have to be exposed to a drug.
- b. The term "side effect," as used in the past, described not only negative (unfavorable) reactions; but, at times, concurrent positive (favorable) effects as well the term should not be regarded as synonymous with ADRs.
- c. ARDs may be explained by one of five mechanisms: (1) "on-target" adverse reactions, (2) "off-target" adverse reactions, (3) cytotoxic reactions, (4) immune-mediated reactions, and (5) idiosyncratic reactions.
- d. A drug or drug class may produce toxic or adverse reactions by one or several of mechanisms of ADRs.

# 3. Which of the following statements related to "on-target" mechanisms of ADRs is correct?

- a. An "on-target" ADRs may occur when a drug interacts with its intended receptor in the intended tissue.
- b. An "on-target" ADR may also occur when a drug interacts with its intended receptor, but in an unintended tissue.
- c. Local anesthetic agents intended to block sodium channels in neuronal tissues at the site of its administration with high plasma levels can cause sodium channel blockade in the heart.
- d. All of the above.

### 4. Which of the following statements related to "off-target" mechanisms of ADRs is correct?

- a. An "off target" ADR can occur when a drug interacts with an unintended receptor either in an intended or in an unintended tissue.
- b. An example of an "off-target" ADR is when a  $\beta_2$ -adrenergic receptor agonist used to treat asthma also interacts with  $\beta_1$ -adrenergic receptors in the heart.
- c. An example of an "off-target" ADR uncovered during post-marketing period, which resulted in the withdrawal of the drug from the market, occurred when terfenadine, an H<sub>1</sub>-histamine receptor blocking agent also interacted with unintended receptors (potassium channels) in an unintended tissue (heart).
- d. All of the above.

## 5. All of the following statements related to cytotoxic mechanism of ADRs specific to APAP toxicity are correct EXCEPT which one?

- a. When APAP undergoes oxidation by CYP450 isoenzyme 2E1 into N-acetyl-pbenzoquinoneimine (NAPQI), this highly reactive metabolite is conjugated into APAPglucuronide and APAP-sulfate.
- b. When glutathione stores are depleted, NAPQI accumulates and attacks cellular and mitochondrial proteins in the liver, which may lead to hepatic fibrosis or necrosis.
- c. Moderate doses of a toxic drug or metabolite activate mechanisms that result in programmed cell death (apoptosis) and tissue fibrosis.
- d. High doses of a toxic drug or metabolite activate mechanisms that lead to uncontrolled cell death and tissue necrosis.

# 6. All of the following statements related to "on-target," "off-target," and cytotoxic ADRs are correct EXCEPT which one?

- a. "On-target," "off-target," and cytotoxic ADRs have a pharmacokinetic or a pharmacodynamic basis.
- b. "On-target," "off-target," and cytotoxic ADRs, with the exception of overdose, are precipitated by drug-drug, drug-food, drug-herbal, and drug-disease interactions with therapeutic doses of a drug.
- c. The risk of ADRs depends on the margin of safety between the dose of a drug required for efficacy and the dose that causes ADRs.
- d. When the margin of safety is small, ADRs result primarily from overdose; when the margin of safety is large, ADRs may manifest at therapeutic doses.

# 7. Which of the following statements related to pharmacokinetic drug-drug interaction is correct?

- a. The plasma level of a drug depends on the dosage administered and the drug's rate of absorption, distribution, metabolism, and clearance.
- b. Pharmacokinetic processes may be altered, i.e., induced or inhibited by drug-drug interactions.
- c. The interaction between opioid analgesics and APAP is an example of a pharmacokinetic drug-drug interaction affecting the absorption of APAP.
- d. All of the above.

# 8. All of the following statements related to pharmacodynamic drug-drug interactions are correct EXCEPT which one?

- a. The intended or unintended effect produced by a given plasma level of a drug may result from chronic use of a drug or the presence of one or more drugs.
- b. Pharmacodynamic ADRs are the result of receptor alterations, and pharmacological, physiological, and chemical drug-drug interactions.
- c. The interaction between NSAIDs and antihypertensive agents is an example of a pharmacological drug-drug interaction.
- d. An example of a beneficial pharmacodynamic drug-drug interaction is illustrated by the interaction between phentolamine mesylate and epinephrine.

# 9. Which of the following statements related to drug-food and drug-herbal interactions is correct?

- a. Nutrients can act as mechanical barriers and protect the gastric mucosa from irritants; but they can also prevent drug-access to mucosal surfaces and reduce or slow the absorption of some drugs.
- b. Components of grapefruit inhibit CYP450 isoenzyme 3A4 and increase the plasma level of a number of drugs; for example, it can significantly enhance the anticoagulant effect of warfarin.
- c. Ginkgo biloba inhibits platelet function; its use with acetylsalicylic acid (ASA), other nonsteroidal antiinflammatory agents (NSAIDs), and clopedigrel, which also interfere with platelet aggregation, increases the risk of bleeding.
- d. All of the above.

### 10. All of the following statements related to cytotoxic ADRs are correct EXCEPT which one?

- a. Depending on the severity of the toxic insult cytotoxicity may manifest as apoptosis, i.e., uncontrolled cell death.
- b. Apoptosis is genetically directed self-destruction of DNA-damaged cells and, may lead to fibrosis.
- c. If the toxic insult is severe, programmed cell death cannot be accomplished and the cells undergo necrosis.
- d. Necrosis is characterized by autolysis of damaged cells, inflammation, and damage to nearby healthy tissues.

### 11. Which of the following statements related to overdose is correct?

- a. Generally, with overdose, the effects of drugs are exaggerated, ADRs become more pronounced, and other, unexpected reactions may be observed.
- b. Nearly half of all opioid overdose deaths are related to prescription opioid analgesics, often in combination with alcohol and sedatives.
- c. An opioid overdose can reliably be identified by the presence of three clinical signs and symptoms referred to as the "opioid overdose triad": (1) pinpoint pupils (miosis), (2) unconsciousness, and (3) respiratory depression.
- d. All of the above.

# 12. All of the following statements related to ADRs affecting oral tissues are correct EXCEPT which one?

- a. Xerostomia (ranked #28) and taste disturbances (ranked #30) are among the 30 most common ADRs identified with the top 200 drugs dispensed by U.S. community pharmacies.
- b. Stomatitis and ulcerative stomatitis represent cytotoxic reactions to topically applied agents, e.g., LAs; or may result from the systemic administration of cytotoxic drugs, e.g., antineoplastic agents.
- c. Antibacterial and corticosteroid therapy is often complicated by superinfection with candidal organisms in oral tissues.
- d. A common ADR related to bisphosphonates is medication-related osteonecrosis of the jaw precipitated by dentoalveolar trauma.

# 13. Which of the following statements related to ADRs affecting the gastrointestinal system is correct?

- a. Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, and anorexia are among the 30 most common potential ADRs associated with therapeutic dosages of the top 200 drugs dispensed by U.S. community pharmacies.
- b. The ulcerogenic effect of NSAIDs is well established and is attributable to inhibition of prostaglan-din synthesis.
- c. Of particular concern to oral healthcare providers should be the patient complaining of lower abdominal pain, acute diarrhea with blood in the stool that is currently taking or has been prescribed in the recent past clindamycin or a broader spectrum penicillin or cephalosporin.
- d. All of the above.

## 14. All of the following statements related to ADRs affecting the liver and biliary system are correct EXCEPT which one?

- a. During the past decade APAP has been identified as the leading cause of acute liver failure (ALF) in the United States and up to 50% of APAP-related cases of ALF are due to unintentional overdose.
- b. Clinical signs and symptoms of APAP overdose include nausea, vomiting, abdominal pain, anorexia, and a few days later, elevated bilirubin presents as jaundice.
- c. The FDA formally withdrew from the market all prescription combination analgesics containing more than 650 mg of APAP per unit dose.
- d. APAP, 650 mg per dose, q4h, may still be prescribed.

# **15.** All of the following statements related to ADRs affecting the ears are correct EXCEPT which one?

- a. Dizziness is the most common potential ADR associated with therapeutic dosages of the top 200 drugs dispensed by U.S. community pharmacies.
- b. Dizziness is an imprecise term describing various related sensations such as faintness, a feeling of impending syncope; light-headedness; and a feeling of imbalance.
- c. Vertigo is described by patients as noise in the ears such as buzzing, ringing, roaring, whistling, hissing, or pulsating.
- d. Potentially ototoxic drugs prescribed by dentist include antibiotics such as metronidazole, clindamycin, and macrolides.

# 16. Which the following statement related to ADRs affecting the cardiovascular and respiratory systems is correct?

- a. Common drugs that produce postural hypotension include diuretics,  $\alpha 1$  and  $\beta 1$ -receptor blockers, nitrates, digitalis, ACE-inhibitors, and calcium channel blockers.
- b. Macrolide antibiotics are known to cause cardiac arrhythmias characterized by prolongation of the QT interval, palpitations, hypotension, and chest pain.
- c. Dyspnea may be caused by drugs prescribed by dentists such as opioids and NSAIDs.
- d. All of the above.

# 17. Which of the following statements related to ADRs affecting the urinary system is correct?

- a. The chronic use of NSAIDs can lead to direct nephrotoxicity called analgesic nephropathy, related to the inhibition of prostaglandin synthetase resulting in reduced glomerular blood flow and acute renal failure.
- b. Urinary incontinence is the involuntary loss of urine diuretics, alcohol, and caffeine increase urine production leading to increased frequency, urgency and nocturia.
- c. Opioid analgesics also can cause urinary retention, and like psychotropic drugs such as benzodiazepines, antidepressants, and antipsychotic agents may affect incontinence by blunting awareness to void.
- d. All of the above.

# 18. All of the following statements related to ADRs affecting the neuropsychiatric system except which one?

- a. Somnolence, sleepiness or drowsiness, is a symptom characterized by a state of strong desire for sleeping or sleeping for unusually long periods.
- b. Insomnia is a symptom characterized by difficulty in falling to sleep or to stay asleep drug-related insomnia may be associated with chronic use of drugs or result from drug withdrawal such as opioid analgesics of benzodiazepines.
- c. Dietary causes of depression include caffeine and monosodium glutamate (Chinese-restaurant syndrome).
- d. Anxiety is the distressing experience of dread and foreboding; unpleasant emotional experience characterized nervousness, uneasiness, and fear.

# 19. All of the following statements related to ADRs affecting the peripheral and central nervous systems are correct EXCEPT which one?

- a. Primary headache may be a symptom of exposure to monosodium glutamate (MSG); analgesic overdose; caffeine withdrawal; and treatment with nitrates.
- b. Symptoms of tardive dyskinesia include oral dyskinesia, i.e., involuntary muscle movements characterized by continual chewing, intermittent darting of the tongue (fly fishing) and lip-smacking, pursing, or puckering.
- c. Drugs associated with paresthesia include LAs, long-term exposure to nitrous oxide, mercury poisoning, led poisoning, anticonvulsant drugs; and withdrawal of benzodiazepines.
- d. Drugs that can increase heat production, i.e., cause fever, include amphetamines, cocaine, general anesthetics, and antipsychotic agents.

# 20. All of the following statements related to ADRs affecting the endocrine/metabolic system are correct EXCEPT which one?

- a. Increased rates of insulin absorption associated with increased skin temperature, heavy exercise, anxiety, infection, and pain lead to hypoglycemia.
- b. Insulin and/or oral hypoglycemic agents in the absence of adequate intake of carbohydrates lead to hypoglycemia.
- c. Glutamate-related manifestations of hypoglycemia include twitching, tremor, anxiety, nervousness, sweating, pallor, cold and clammy skin, and mydriasis.
- d. Neuroglycopenic manifestations include fatigue, weakness, lethargy, paresthesia, headache, reduced mental capacity, impairment of action and judgment, focal or generalized seizure, and coma.

## References

- 1. Leape L, Abookire S, World Health Organization, et al. WHO draft guidelines for adverse event reporting and learning systems : from information to action. Geneva, Switzerland : World Health Organization. 2005.
- 2. U.S. Food and Drug Administration. Guideline for Industry. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Accessed June 12, 2017.
- 3. Mayo Clinic. Statistics about adverse reactions. Prevalence and incidence statistics for adverse reactions. Accessed June 12, 2017.
- 4. Valhe JL, Hutto DL, Postema M. Drug discovery and preclinical development- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 919-932.
- 5. Goldberg MA, Kuta AE. Clinical drug evaluation and regulatory approval- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 933-945.
- 6. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 70-86.
- 7. Guengerich FP. Drug metabolism- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 43-55.
- 8. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Accessed June 12, 2017.
- 9. Roswarski M, Villa KR, Kiersma ME, et al. Prevalence of Adverse Drug Effects/Adverse Drug Reactions in 200 Most Commonly Prescribed Drugs Corrected for Prescription Volume. 2009. Pharmacy Practice Faculty Presentations. 69. Accessed June 12, 2017.
- 10. National Institute of Health. U.S. National Library of Medicine. DailyMed. Accessed June 12, 2017.
- 11. Centers for Disease Control and Prevention. Opioid overdose. Accessed June 12, 2017.
- 12. World Health Organization. Information sheet on opioid overdose. November, 2014. Accessed June 12, 2017.
- 13. Ciancio SG. Medications' impact on oral health. J Am Dent Assoc. 2004 Oct;135(10):1440-8; quiz 1468-9.
- 14. Jacobsen PL, Chávez EM. Clinical management of the dental patient taking multiple drugs. J Contemp Dent Pract. 2005 Nov 15;6(4):144-51.
- 15. Torpet LA, Kragelund C, Reibel J, et al. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004 Jan 1;15(1):28-46.
- 16. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004 Jul 1;15(4):221-39.
- 17. American Association of Oral and Maxillofacial Surgeons. Medication-Related Osteonecrosis of the Jaw 2014 Update. Accessed June 12, 2017.
- Greenberger NJ. Approach to the patient with upper GI complaints The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 70-83.
- 19. Bharucha AE. Approach to the patient with lower GI complains The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 83-93.
- 20. Ansari P. Acute abdominal and surgical gastroenterology - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 105-119.
- 21. Freedman SD. Pancreatitis The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 140-145.
- 22. Cohen S. Gastritis and peptic ulcer disease The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 128-137.

- 23. FDA Drug Safety Communication:Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. 01/13/2011 Accessed June 16, 2017
- 24. Herrine SK. Navarro VJ. Drugs and the liver The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 232-235.
- 25. Tucci DL. Approach to the patient with ear problems The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 413-428.
- 26. Tanser PH. Approach to the cardiac patient The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2017-2047.
- 27. Mitchell LB. Arrhythmias and conduction disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2142-2178.
- 28. Lechtzin N. Approach to the patient with pulmonary symptoms The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1826-1847.
- 29. McMillan JI. Glomerular disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2387-2411.
- 30. Lui PD. Voiding disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2352-2364.
- Doghramji K. Sleeping and wakefulness disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1703-1714.
- 32. Coryell W. Mood disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1538-1552.
- 33. Greist JH, Jefferson JW. Anxiety disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1493-1501.
- 34. Silberstein SD. Headache The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1715-1725.
- 35. Jacewitcz M. Approach to the neurologic patient The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1586-1605.
- 36. Eidelberg D, Pourfar M. Movement and cerebellar disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1759-1778.
- 37. Rubin M. Peripheral nervous system and motor unit disorders The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1784-1803.
- 38. Tunkle AR. Biology of infectious diseases The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1148-1165.
- 39. Crandall JP. Diabetes mellitus and disorders of carbohydrate metabolism The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 866-888.

## **About the Authors**

### Kristin A. Williams, DDS, MPH



Dr. Kristen A. Williams is an Assistant Professor, Department of Community Dentistry, and Assistant Dean for Admissions and Student Affairs at Case Western Reserve University, School of Dental Medicine in Cleveland, OH. Dr. Williams received her D.D.S. in 1989, completed a residency in Dental Public Health, and obtained a Master of Public Health in 2005, all at the School of Dental Medicine, Case Western Reserve University. Dr. Williams holds several positions in local professional societies, serves as a reviewer for national public health publications, published extensively in peer-reviewed journals, and presented many scientific

programs at local, state and national professional meetings.

Email: kaw14@case.edu

### M. Louay Taifour, BDS, DMD



Dr. Taifour earned his dental degree from Beirut Arab University School of Dental Medicine, then completed an AEGD residency and a Restorative Fellowship at Case Western Reserve School of Dental Medicine. Dr. Taifour teaches several pre-doctoral courses and is a full time clinical attending for the AEGD residency program.

Email: mohammedlouay.taifour@case.edu